Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
By R. Holloway, I. Shoulson, K. Kieburtz, M. Mcdermott, P. Tariot, Cornelia L. Kamp, D. Day, A. Shinaman, S. Fahn, A. Lang and 59 more. Journal of the American Medical Association (JAMA), 2000
961 citations recorded by the source corpus.
Subfields: Neurology
View Paper: https://www.semanticscholar.org/paper/20c870d5259fec1e5299e89e063d81d758902108
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Neurology
Citations in the corpus
- Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. (2004, methodology): “A report detailing the methods and results of the first 2 years of this clinical trial has been previously published.(2,3) After 2 years, initial pramipexole resulted in the significantly reduced risk of the development of wearing off, dyskinesias, or on-off motor fluctuations compared with levodopa”